Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.495
+0.035 (1.01%)
Aug 8, 2025, 11:52 AM - Market open
Sumo Logic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
56
Market Cap
299.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
Dec 31, 2020 | 48.63M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AVIR News
- 19 hours ago - Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 - GlobeNewsWire
- 6 weeks ago - Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewsWire
- 4 months ago - Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewsWire